Extension of the RENACER Study: 12-Month Efficacy, Safety and Certolizumab PEGol Survival in 501 Rheumatoid Arthritis Patients
Reumatol Clin
.
2021 Jan;17(1):57-58.
doi: 10.1016/j.reuma.2018.12.004.
Epub 2019 Jan 28.
[Article in En, Spanish]
Authors
Vicenç Torrente-Segarra
1
,
Manuel Fernández Prada
2
,
Rosa Expósito
3
,
Noemí Patricia Garrido Puñal
4
,
Amalia Sánchez-Andrade
5
,
José Ramón Lamúa-Riazuelo
6
,
Alejandro Olivé
7
,
Juan Víctor Tovar
8
,
RENACER Study Group
Affiliations
1
Hospital Comarcal Alt Penedès, Spain. Electronic address: vtorrente@hsjdbcn.org.
2
Hospital Universitario de Guadalajara, Spain.
3
Hospital Comarcal de Laredo, Spain.
4
Hospital Universitario Virgen del Rocío, Spain.
5
Complejo Hospital Universitario Lucus Augusti, Spain.
6
Hospital Universitario del Henares, Spain.
7
Hospital Germans Tries i Pujol, Spain.
8
Hospital General Universitario de Elche, Spain.
PMID:
30704922
DOI:
10.1016/j.reuma.2018.12.004
No abstract available
Publication types
Letter